Therapy and Clinical Studies

48 Items

All Items

Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study

Nargiz Majidova, Mustafa Seyyar, Demet Işık Bayraktar, Gülhan Dinç, Elfag İsgandarov, Javid Huseynov, Alper Yaşar, Abdussamet Çelebi, Nadiye Sever, Erkam Kocaaslan, Pınar Erel, Yeşim Ağyol, Ali Kaan Güren, Rukiye Arıkan, Selver Işık, Özlem Ercelep, Güzin Demirağ, Umut Kefeli, Osman Köstek, İbrahim Vedat Bayoğlu, Murat Sarı

1776–1784
Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy

Semir Vranic, Zoran Gatalica

673–675
Treatment outcome of elderly patients (≥ 78 years) with head and neck squamous cell carcinoma: A single center experience

Yi Liu, Dan Wang, Yue Deng, Shichuan Zhang

1417–1423
The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis

Yan Zhu, Chongyang Wang

2428–2438
The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review

Hastono Ridwansyah, Indra Wijaya, Muhammad Hasan Bashari, Achmad Hussein Sundawa Kartamihardja, Bethy Suryawathy Hernowo

727–739
The prognostic role of the change in albumin-derived neutrophil-to-lymphocyte ratio during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer

Zhen Pan, Ye Wang, Shoufeng Li, Huajun Cai, Guoxian Guan

612–624
The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis

Zhitao Yan, Xiaona Xing, Jinmei Huang

1723–1736
The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances

Maja Pezer Naletilić, Krešimir Tomić, Kristina Katić, Zoran Gatalica, Gordan Srkalović, Eduard Vrdoljak, Semir Vranić

2594–2606
TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction

Yuanbin Chen, Xiaolong Wang, Jin Chen, Min Dai, Xinyue Zhang, Jie Yin, Xiao He

1868–1881
Surgical approach and recurrence risk in struma ovarii: A retrospective and systematic analysis

Miao Ao, You Wu, Zhiping Huo, He Zhang, Wei Mao, Bin Li

1092–1098
Small cell lung cancer (SCLC): At the door of targeted therapies

Krešimir Tomić, Semir Vranić

1–4
Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes

Semir Vranic

189–190
Risk and prognosis of second cutaneous melanoma after radiotherapy for breast cancer: A population-based analysis

Tianxin Luo, Yani Zhang, Tianliang Chen, Yanxia Cai, Zheng Yang

959-967
Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

Yu-Quan Li, Xue-Mei Chen, Gui-Fei Si, Xue-Min Yuan

764-774
Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP

Hui Su, Chao Yu, Guiming Sun, Baozhong Wang, Yingjie Gao, Xiaolan Liu, Qingcui Song, Xuezhen Ma

29–41
$Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study$

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Sabin Goktas Aydin, Engin Eren Kavak, Atakan Topcu, Ayberk Bayramgil, Fahri Akgul, Seda Kahraman, Musa Baris Aykan, Yunus Emre Altıntas, Kaan Helvaci, Yuksel Urun, Ahmet Bilici, Mesut Seker, Mehmet Ali Nahit Sendur, Omer Fatih Olmez, Ozgur Acikgoz, Irfan Cicin

1089–1095
Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

Marija Kraljević, Inga Marijanović, Maja Barbarić, Emir Sokolović, Merima Bukva, Timur Cerić, Teo Buhovac

161-169
Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study

Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen, Xiangdong Cheng

153-160
Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index

Nulifer Kilic Durankus, Efsun Somay, Sibel Bascil, Sukran Senyurek, Duriye Ozturk, Ugur Selek, Erkan Topkan

240–248
Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

Jiefeng Weng, Hui Liu, Zhaofeng Wu, Yu Huang, Shuai Zhang, Yujie Xu

857–868

1-20 of 48 Next

Therapy and Clinical Studies

All Items

Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multi-centre study

Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy

Treatment outcome of elderly patients (≥ 78 years) with head and neck squamous cell carcinoma: A single center experience

The role of COPD in survival of NSCLC patients receiving immune checkpoint inhibitors: A meta-analysis

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review

The prognostic role of the change in albumin-derived neutrophil-to-lymphocyte ratio during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer

The influence of sodium-glucose co-transporter-2 inhibitors on the risk of cancer therapy-related cardiac dysfunction: A meta-analysis

The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances

TCF12 enhances angiogenesis and affects sorafenib response in liver cancer via HIF-1α interaction

Surgical approach and recurrence risk in struma ovarii: A retrospective and systematic analysis

Small cell lung cancer (SCLC): At the door of targeted therapies

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes

Risk and prognosis of second cutaneous melanoma after radiotherapy for breast cancer: A population-based analysis

Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study

Predicting osteoradionecrosis risk in patients with locoregionally advanced nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: The value of the CARWL index

Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

impact_factor_6

Sidebar_menu